Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Conflict of interest
- Prion-like propagation of Parkinson's disease (1)
- Prion-like propagation of Parkinson's disease (2)
- Progression of Parkinson's disease
- Parkinson's disease: symptoms and pathology
- Braak staging of Lewy-related pathology in PD
- Lewy bodies in grafted neurons
- The prion-like hypothesis
- Lewy bodies in the substantia nigra and the graft
- All markers consistent with Lewy bodies
- α-synuclein accumulation in the host brain
- Increased cytoplasmic α-syn during normal aging
- α-synuclein accumulation in grafted neurons
- Time-dependent increase in pathology
- Prion-like behavior of α-synuclein: basic scheme
- Cell culture models: α-synuclein transfer (1)
- Cell culture models: α-synuclein transfer (2)
- Cells from different species as a model system
- Transmitted α-syn: possible aggregation seeder (1)
- Transmitted α-syn: possible aggregation seeder (2)
- Cell culture models are very informative
- In vivo models offer additional dimensions
- Tracking α-synuclein transfer using a rat model
- Evidence for α-synuclein transfer
- High rate of intercellular α-synuclein transfer
- Possible α-synuclein seeding in vivo
- Oligodendrocytes take up exogenous α-synuclein
- A dynamic equilibrium
- α-synuclein transfer in a mouse model
- Graft model features
- Pathological α-syn initiates fast neurodegeneration
- Propagation of pathological α-syn
- Pathologic α-syn initiates PD-like degeneration
- Accelerating α-synucleinopathy in mouse model
- Synucleinpathies may be prion-like disorders
- α-synuclein injections into olfactory bulb
- α-synuclein (oligomer) injection
- Injection of α-syn "preformed fibril" (PFF)
- How α-synuclein might enter cells
- Endocytosis & clearance of extracellular α-syn
- Endocytosis inhibitors reduce cell-to-cell transfer
- Endocytosis plays a role in α-syn transfer in vivo
- Other mechanisms for α-synuclein to enter cells
- Exosomes (1)
- Exosomes (2)
- How we may affect this prion-like behavior
- Braak staging: progression of α-syn pathology
- Therapeutic targets
- Mediators of proteopathic seed uptake
- Proteopathic seed uptake via HSPG binding
- HSPGs mediate uptake of α-synuclein
- Cell culture models: high throughput screening
- Therapeutic targets: promoting degradation
- Origins and effects of extracellular α-synuclein
- Antibody aided clearance of extracellular α-syn
- Systemic Ab274 passive immunization: effects
- Parkinson’s vaccine: first clinical studies
- Therapeutic targets: preventing seeding
- Anle138b: modulating α-syn oligomerisation
- Effects of anle138b in A30P α-syn mice
- Concluding remarks
- Acknowledgements
- Thanks
Topics Covered
- Parkinson's disease: symptoms and pathology (PD mutations and risk factors)
- Braak staging of Lewy body-related pathology in PD
- The prion-like hypothesis
- Key steps of alpha-synuclein pathology propagation (Release, Uptake, Seeding, Transport)
- In vivo and cell models from different species
- Therapeutic targets: promoting degradation, antibody aided clearance, and preventing seeding of alpha-synuclein
- Parkinson’s disease vaccine: first clinical studies
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Brundin, P. (2014, June 2). Prion-like propagation of Parkinson's disease [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 26, 2024, from https://doi.org/10.69645/NWVM5857.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Patrik Brundin has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Clinical Practice
Transcript
Please wait while the transcript is being prepared...
0:00
Welcome to this presentation,
which is entitled "Prion-like
Propagation of Parkinson's Disease."
My name is Patrik Brundin.
I am at the Center for
Neurodegenerative Science at Van
Andel Institute in
Grand Rapids, Michigan.
I also have an affiliation
with Lund University in Sweden.
0:24
So this story begins
about six years ago.
We had submitted a manuscript
entitled "Lewy bodies
in long-surviving mesencephalic
grafts for Parkinson's disease
may suggest prion-like propagation."
The reviewers at
"Nature Medicine" found
this to be an
interesting observation.
And all three of them thought
it should be published.
However, one reviewer pointed
out that "On page five,
the discussion of potential
mechanisms for the phenomenon
is interesting and appropriate."
But "thereafter, the discussion
of prion-like propagation
of pathology into
grafted neurons ventures
into unsubstantiated fantasy--
the 'prion hypothesis'
should be limited to no more than
three sentences and reference to it
should be removed from
the title-- In fact,
I think there were about 11
sentences dealing with this.
And we ended up with
maybe three or four.
We did indeed remove
it from the title.
1:17
Finally, the paper was published--
not using the word prion
or prion-like in the title and
barely discussing the hypothesis--
just mentioning it in passing.
1:30
So the themes for today's talk are
really to "focus on the progression
of Parkinson's disease," and in
doing so, "injecting substance
into the unsubstantiated fantasy"
that I just mentioned-- namely,
that Parkinson's disease might
be a prion-like disorder.
Finally, I will spend
some time discussing
what we can do about this.
Is this opening up
avenues for new therapies?
I will begin by describing
progression of Parkinson's disease
and putting it in context of what
this disorder is really about.